![]() |
![]() |
![]() |
![]() |
P01-01 | In vitro and in vivo models of hepatitis B virus (HBV) replication utilising monomeric HBV genomes to facilitate studies of the HBV cccDNA minichromosome. | Peter Revill | ![]() |
![]() |
|||
P03-01 | Evaluation of the Safety and Tolerability of Transaminase Flares During Antiviral Therapy in Patients with HBeAg Negative Chronic HBV Infection or HBV / HDV Co-infection | Andrew Vaillant | ![]() |
![]() |
|||
P04-01 | Hepatitis B core-related antigen quantification is an accurate predictor 12-months prior to hepatitis B e antigen-seroclearance in human immunodeficiency virus/hepatitis B coinfected patients treated with tenofovir | Lorenza Dezanet | ![]() |
![]() |
|||
OP-01 | A novel pyrazole HBV nucleocapsid formation inhibitor demonstrating high activity against HBV variants that are resistant to class I and class II core protein allosteric modulators | Zhijun Zhang | ![]() |
![]() |
|||
P06-01 | Hepatitis B virus infection as a trigger of hepatocyte identity loss | Chloe Goldsmith | ![]() |
![]() |
|||
P04-02 | Anti-hepatitis B core antibody titer and interleukin-10 quantification as predictors of hepatitis B e antigen-seroclearance in human immunodeficiency virus/hepatitis B coinfected patients treated with tenofovir | Lorenza Dezanet | ![]() |
![]() |
|||
P06-02 | Serum M2BPGi as a diagnostic marker of liver fibrosis in patients with chronic hepatitis B | Natthaya Chuaypen | ![]() |
![]() |
|||
P03-02 | Efficient Clinical Development of More Curative HBV Therapies | Nathaniel Brown | ![]() |
![]() |
|||
OP-02 | Establishment of High Rates of Functional Cure of HBeAg Negative Chronic HBV Infection with REP 2139-Mg Based Combination Therapy: Ongoing Follow-up Results from the REP 401 Study | Andrew Vaillant | ![]() |
![]() |
|||
P01-03 | HBV RNA at 6 months predicts HBeAg loss in nucleos(t)ide analogue treated HBeAg positive patients: demonstration of clinical utility? | Bo Wang | ![]() |
![]() |
|||
P06-03 | Association between Hepatitis B Virus preS2 deletion and increased risk of Hepatocellular Carcinoma: a case-control study in West Africa | Damien Cohen | ![]() |
![]() |
|||
P03-03 | Prediction of HBeAg loss on long-term nucleos(t)ide analogues with a novel HBV pgRNA assay | Daryl Lau | ![]() |
![]() |
|||
P04-03 | Serum HBV RNA and HBcrAg: new markers for predicting incomplete HBV DNA suppression after initiation of nucleoside therapy in HIV/HBV co-infected individuals. | Ruth Byrne | ![]() |
![]() |
|||
OP-03 | Pre-genomic HBV RNA and HBcrAg play important role in the predicting clinical outcomes in chronic hepatitis B patients suppressed on antiviral therapy with nucleos(t)ide analogues | Ivana Carey | ![]() |
![]() |
|||
P02-03 | The gamma glutamyl transpeptidase to platelets ratio and gamma glutamyl transpeptidase to albumin ratio do not correlate to fibroscan measurement of hepatic fibrosis in chronic hepatitis b egyptian patients: a pilot study | Mohammed Elhendawy | ![]() |
![]() |
|||
OP-04 | Hepatitis B core-related antigen correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients | Barbara Testoni | ![]() |
![]() |
|||
P02-04 | Core outcome set for Cochrane reviews on chronic hepatitis B infection | Mirella Fraquelli | ![]() |
![]() |
|||
P01-04 | Dynamic changes of serum HBV pgRNA levels in patients with chronic hepatitis B treated with entecavir or peg-interferon | Xiaoqi Yu | ![]() |
![]() |
|||
P04-04 | Genetic variation in STAT4 is associated with treatment response to pegylated interferon in patients with chronic hepatitis B | Natthaya Chuaypen | ![]() |
![]() |
|||
P06-04 | The effect of diabetes mellitus on treatment course of chronic hepatitis B and their clinical profile | Ibtehaj Alharbi | ![]() |
![]() |
|||
P03-04 | Diagnostic accuracy of aspartate transaminase to platelet ratio index ,fibrosis index based on 4 factors (fib-4) and golgi protein 73 for prediction of significant liver fibrosis in chronic hepatitis b patients:an egyptian cross-sectional study | Rahma Mohamed | ![]() |
![]() |
|||
P02-05 | outcomes of severe acute viral hepatitis b in latvia | Jekaterina Kucina | ![]() |
![]() |
|||
P04-05 | Evaluation of serum alanine aminotransferase level in treated chronic hepatitis B patients | Wanna Yang | ![]() |
![]() |
|||
P03-05 | Serum sulfatase-2 is a new prognostic marker of patients with hepatitis B Virus-related hepatocellular carcinoma | Natthaya Chuaypen | ![]() |
![]() |
|||
P01-05 | Adverse events of nucleos(t)ide analogues for chronic hepatitis B: a systematic review | Raquel Scherer de Fraga | ![]() |
![]() |
|||
P06-05 | Mean Week 24 HBsAg declines predict subsequent rate of HBsAg seroclearance and could be a valuable endpoint for early development hepatitis B virus trials | Gail Edwards | ![]() |
![]() |
|||
OP-05 | TherVac B - an optimized therapeutic vaccine for hepatitis B | Ulrike Protzer | ![]() |
![]() |
|||
OP-06 | Investigating the role of HBsAg on cellular immune responses in HBeAg negative patients with chronic hepatitis B to define HBV treatment endpoints | Elmira Aliabadi | ![]() |
![]() |
8-9 March 2019 London
![]() |
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. ![]() To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress. ![]() |
![]() |
||
![]() |
|